S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)

Tango Therapeutics Stock Price, News & Analysis (NASDAQ:TNGX)

$7.76
+0.16 (+2.11%)
(As of 12/1/2023 ET)
Compare
Today's Range
$7.44
$7.87
50-Day Range
$6.52
$12.01
52-Week Range
$2.47
$13.03
Volume
452,879 shs
Average Volume
625,197 shs
Market Capitalization
$791.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.2% Upside
$16.00 Price Target
Short Interest
Bearish
18.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$8.72 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.05) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

629th out of 957 stocks

Pharmaceutical Preparations Industry

298th out of 443 stocks


TNGX stock logo

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

TNGX Stock News Headlines

Tango Therapeutics (NASDAQ:TNGX) Shares Down 3.6%
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Tango Therapeutics: Q3 Earnings Insights
Tango Therapeutics Inc TNGX
Circling Bank On Tango Therapeutics
Tango Therapeutics (NASDAQ: TNGX)
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+106.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-108,180,000.00
Net Margins
-266.73%
Pretax Margin
-266.36%

Debt

Sales & Book Value

Annual Sales
$24.86 million
Book Value
$2.71 per share

Miscellaneous

Free Float
95,667,000
Market Cap
$791.44 million
Optionable
Not Optionable
Beta
0.86
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 66)
    President, CEO & Director
    Comp: $941.16k
  • Ms. Daniella Beckman CPA (Age 44)
    Chief Financial Officer
    Comp: $619.13k
  • Dr. Alan Ashworth FRS (Age 62)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D. (Age 54)
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 65)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 56)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Jannik N. Andersen Ph.D.
    Chief Scientific Officer
  • Mr. Douglas J. Barry Esq. (Age 53)
    J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
  • Mr. John C. Ross M.S.
    Vice President of Human Resources














TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2023?

Tango Therapeutics' stock was trading at $7.25 on January 1st, 2023. Since then, TNGX shares have increased by 7.0% and is now trading at $7.76.
View the best growth stocks for 2023 here
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our TNGX earnings forecast
.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm earned $10.73 million during the quarter, compared to the consensus estimate of $8.05 million. Tango Therapeutics had a negative net margin of 266.73% and a negative trailing twelve-month return on equity of 41.41%.

What ETF holds Tango Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.42%), Adage Capital Partners GP L.L.C. (1.72%), Deerfield Management Company L.P. Series C (0.78%), Invesco Ltd. (0.76%), Northern Trust Corp (0.39%) and Charles Schwab Investment Management Inc. (0.36%). Insiders that own company stock include Adam Crystal and Boxer Capital, Llc.
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -